Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis

Journal of Endocrinological Investigation

Volumn 31, Issue 5, 2008, Pages 416-421

  Fernandez Garcia D ^a   Munoz Torres M ^a,c   Mezquita Raya, P ^a   de la Higuera, M ^a   Alonso, G ^a   Reyes Garcia R ^a   Ochoa, A Sebastian ^a   Ruiz Requena, M E ^a   Luna, J Dios ^b   Escobar Jimenez F ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c School of Medicine ^*  (Spain)

Author keywords

Bone mineral density; Osteoprotegerin; Post menopausal osteoporosis; Raloxifene; RANK L

Indexed keywords

25 HYDROXYVITAMIN D; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RALOXIFENE; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; HEART ATRIUM FIBRILLATION; HIP; HUMAN; LUMBAR SPINE; OSTEOCLAST; PARACRINE SIGNALING; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; THROMBOEMBOLISM;

EID: 48949117005     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346385     Document Type: Article

References (24)

1. Hofbauer LC, Khosla S, Dunstan CR, Lacey D, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15: 2-12.
2. Khosla S. The OPG/RANKL/RANK system. Endocrinology 2001, 142: 5050-5.
3. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000, 289: 1504-8.
4. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23: 279-302.
5. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140: 4367-70.
6. Shevde NK, Bendixen A, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 2000, 97: 7829-34.
7. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19: 1059-66.
8. Eghbaii-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111: 1221-30.
9. Ettinger B, Black D, Cummings S, Genant H, Gluer C, Lips P and the MORE study group. Raloxifene reduces the risk of incident vertebral fractures: 24 month interim analyses. Ost Int 1998, 8 (Suppl 3): 11 (abstract).
10. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282: 637-45.
11. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Eng J Med 2003, 348: 618-29.
12. McDonnell DP. Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replaxement therapy regimen. J Soc Gynecol Invest 2000, 7 (1 Suppl): S10-5.
13. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Enclocrinol 2003, 177: 423-33.
14. Viereck V, Gründker C, Blashke S, et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Enclocrinol Metab 2003, 88: 4206-13.
15. Bashir A, Mak YT, Sankaralingam S, et al. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. Steroids 2005, 70: 847-55.
16. Messalli EM, Mainini G, Scaffa C, et al. Raloxifene theraphy interacts with serum osteoprotegerin in postmenopausal ostoporosis. Maturitas 2007, 56: 38-44.
17. Mezquita-Raya P, de la Higuera M, Fernández-Garcia D, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 2005, 6: 1368-74.
18. Compston JE. Sex esteroides and bone. Physiol Rev 2001, 81: 419-47.
19. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292: 490-5.
20. Naylor KE, Rogers A, Fraser RB, Hall V, Eastell R, Blumsohn A. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Enclocrinol Metab 2003, 88: 5361-5.
21. Hegedus D, Ferencz V, Lakatos PL, et al. Decreased bone density, elevated serum osteoprotegerin, and b-cross-laps in Wilson disease. J Bone Miner Res 2002, 17: 1961-7.
22. Hofbauer LC, Schoppet M, Schüller P, Viereck V, Christ M. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Enclocrinol (Oxf) 2004, 60: 214-9.
23. Hofbauer LC, Dunstan CR; Spelberg TC, Riggs BL, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein 2, and cytokines. Byochem Biophys Res Commun 2001, 280: 334-9.
24. Kitazawa S, Kajimoto K, Kondo T, Takeshi Kondo, Kitazawa R. Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem 2003, 89: 771-7.